ArticleBMC infectious diseases2025
Ongoing presence of Leishmania major cutaneous leishmaniasis in Mauritania, 2016-2024.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New Thieno[3,2-Life (Basel, Switzerland) · 2026Article
- Evidence Gaps and Global Patterns in Leishmaniasis Control: A Scoping Review of Clinical, Diagnostic, and Treatment Strategies.Journal of parasitology research · 2026Review
- Molecular diagnostics for cutaneous leishmaniasis: progress towards fulfilling the WHO target product profile.Parasitology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the presence of biologically confirmed cases, cutaneous leishmaniasis (CL) is still absent from the annual health statistical reports of the Ministry of Health in Mauritania. This study aimed to confirm the presence of CL in patients with compatible skin lesions in Mauritania.
methodsThis cross-sectional descriptive study was conducted between September 2022 and August 2023 and between March and August 2024. It involved subjects with compatible skin lesions who attended dermatological consultations at various healthcare facilities in the Nouakchott and Assaba regions. In parallel, a retrospective study (2016-2024) analyzed data from suspect cases who visited the National Institute of Research in Public Health for laboratory diagnosis of CL infection. Biological confirmation was performed through microscopy using May-Grünwald Giemsa staining. During the cross-sectional study, PCR targeting the 3'UTR-Hsp70 region was also performed on filter papers used for dried blood spot.
resultsAmong the 37 suspected patients seen in dermatological consultation, 21 (57%) were female and 16 (43%) were male. The mean age of the subjects was 29 ± 18.4 with a median of 28 years. Skin smears from suspect lesions were positive in 21 (56.7%) patients while the PCR showed only 12 (40%) positive patients. Cutaneous Leishmaniasis infection was higher among women (66.6%) than men (33.3%) (combining microscopy and PCR). Leishmania major was the only encountered species. Skin lesions were dry in 38.1% (8/21), crusted in 33.3% (7/21) and superinfected in 28.6% (6/21) of the microscopy-positive CL cases. Of 21 microscopy-positive cases, 38.1% (8/21) had skin lesions in upper limbs, 47.6% (10/21) in lower limbs and 14.3% (3/21) in both upper and lower limbs. The majority of confirmed CL patients (61.9%; 13/21) had more than 2 skin lesions. In the retrospective study, 95 suspect cases of CL were identified between 2016 and 2024, including 48 (47.1%) cases confirmed by microscopy. These cases mainly came from the southern regions of Mauritania, such as Assaba (n = 15) and Grogol (n = 12).
conclusionThe study confirms the ongoing presence of CL in Mauritania, particularly in the southern areas and provides confirmation of the presence of L. major. It underscores the urgent need to locally develop appropriate diagnostic tools and to authorize the commercialization of meglumine antimoniate in the country. Further studies should be conducted to better determine the disease burden, identify vectors and reservoirs and evaluate therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.